The worldwide exclusive license covers the marketing, sale and distribution of adult Arctic ground squirrel (AGS) neural stem cells for research use and provides Neuronascent with license fees and royalty income.
The Arctic ground squirrel is the only known mammal capable of lowering its body temperature to below freezing during hibernation. Scientists believe that this tolerance makes AGS cells a unique clinically-relevant model for the study of cerebral ischemia. Dr. Kelly Drew, a collaborator from the University of Alaska-Fairbanks and the Institute for Arctic Biology, summed it up by saying, "Neuronascent has captured tolerance to cerebral ischemia in a neural stem cell line derived from Arctic ground squirrels. This unique extremophile can now be explored by scientists throughout the world."
"Neuronascent is excited to partner with Lifeline Cell Technology in the commercialization of this unique and useful product," said Judith Kelleher-Andersson, Ph.D., President and Chief Scientific Officer of Neuronascent. Dr. Kelleher-Andersson went on to say, "We hope this agreement provides for the distribution of a new research tool for identifying novel therapeutic targets and for animal transplantation research."